Bionano Genomics (BNGO) Q3 2026 earnings summary

Executive summary

• Q3 revenue was $8.276M, up 12% YoY; flow-cell sales rose 18% to a quarterly record of 9,870, and adjusted gross margin increased to 48%.

• Q3 net loss narrowed to $6.453M from $8.503M; 9M revenue rose 13% to $23.134M, while 9M net loss widened to $22.179M.

Financial highlights

• Q3 GAAP revenue was $8.276M vs. $7.367M; GAAP gross profit was $3.949M vs. $3.370M.

• Operating expenses decreased 12% YoY to $10.5M; adjusted operating expenses were $8.807M vs. $9.658M, down 9%.

• Q3 net loss was $6.453M vs. $8.503M; 9M net loss was $22.179M vs. $18.462M.

• 9M revenue was $23.134M vs. $20.557M; operating loss was $21.651M vs. $24.803M.

Outlook and guidance

• FY 2026 revenue guidance was reiterated at $31M–$33M, representing 9%–16% growth over 2025; results were expected near the midpoint.

• Current plans indicate funding for operating expenses and capital needs into at least Q1 2027, but additional capital is needed to support operations beyond the next 12 months.

• Production constraints are expected to ease toward year-end; capacity is planned to double by mid-2027 and cover projected 2027 demand and most of 2028.

• Ionic System for OGM is planned for limited market release in Q4 2026.